Accelr8 Technology Corporation
7000 North Broadway
Building 3-307
Denver
Colorado
80221
United States
Tel: 303-863-8088 or 800-582-8898
Fax: 303-863-1218
Website: http://www.accelr8.com/
66 articles about Accelr8 Technology Corporation
-
Accelr8 Technology Corporation Announces NASDAQ Capital Market Listing
12/13/2012
-
Accelr8 Technology Corporation to Hold 2012 Annual Meeting of Shareholders; Product Development Continues with Launch Expected in 2015
12/12/2012
-
Accelr8 Technology Corporation Plans to Grow in AZ; Aims to Hire 300 in the Next Few Years
8/17/2012
-
Accelr8 Technology Corporation Appoints Steve Reichling Chief Financial Officer
8/10/2012
-
Accelr8 Technology Corporation Names Dr. Matthew Strobeck to Board of Directors
7/11/2012
-
Accelr8 Technology Corporation Names Lawrence Mehren CEO
6/27/2012
-
Accelr8 Technology Corporation Closes on Investment
6/27/2012
-
Accelr8 Technology Corporation Presents Two Studies at American Society for Microbiology 2012 and Receives Acceptance to Present a New Blood Study
6/22/2012
-
Accelr8 Technology Corporation and Denver Health Notified by Department of Defense for Rapid Diagnostics Award
5/15/2012
-
Accelr8 Technology Corporation to Get $35 Million Private Equity Investment, New Execs
4/25/2012
-
Accelr8 Technology Corporation Announces Development Expansion for Blood-Based Diagnostic Tests
11/22/2011
-
Accelr8 Technology Corporation Announces Interim Plan and Advanced Studies
10/13/2011
-
Accelr8 Technology Corporation Announces Renewal and Expansion of SCHOTT Microarray License, and Notice of Allowance for New Patent
9/22/2011
-
Accelr8 Technology Corporation Announces Results in Award-Winning Presentation for Rapid Diagnostics with ICU Specimens
9/19/2011
-
Accelr8 Technology Corporation Announces Continuation and Expansion of BACcel(TM) Development Collaboration
7/25/2011
-
Accelr8 Technology Corporation to Receive Award for ICAAC Presentation
7/18/2011
-
Accelr8 Technology Corporation Announces Continuation of BACcel(TM) Collaboration
7/1/2011
-
Accelr8 Technology Corporation States That Its Policy is not to Comment on Unusual Market Activity or Rumors
6/9/2011
-
Accelr8 Technology Corporation 4-Hour Test Identifies New Drug-Resistant “Staph” (hVISA) Undetectable by Hospital Labs
5/23/2011
-
Accelr8 Technology Corporation States That Its Policy is Not to Comment on Unusual Market Activity or Rumors
5/20/2011